Sugi Predict

Sugi Predict / Compounds / SCHEMBL3948255

SCHEMBL3948255

SCHEMBL3948255

CC(=O)OCC1OC(n2cnc3c(Cl)nc(Cl)nc32)C(OC(C)=O)C1OC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 1.00
▸ TP53 P04637 2/20 1.00
▸ ALDH1A1 P00352 2/20 1.00
▸ MAPT P10636 1/20 1.00
▸ TDP1 Q9NUW8 1/20 1.00
▸ ACHE P22303 5/20 0.54
▸ PRKAB2 O43741 1/20 0.53
▸ PRKAG1 P54619 1/20 0.53
▸ PRKAA2 P54646 1/20 0.53
▸ PRKAA1 Q13131 1/20 0.53
▸ PRKAG3 Q9UGI9 1/20 0.53
▸ PRKAG2 Q9UGJ0 1/20 0.53
▸ PRKAB1 Q9Y478 1/20 0.53
▸ THRB P10828 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ ADORA3 P0DMS8 4/20 0.46
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA4 P22748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29609278 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL5983791 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL3770300 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL13012214 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL13062149 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL24371902 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL6884789 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL21798516 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL22826797 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1
SCHEMBL5410879 1.00 LMNA (1.00) LMNATP53ALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
US-20220378816-A1 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGONISTIC ACTIVITY ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2022-12-01 — — US disclosed
US-20090156544-A1 A1 ADENOSINE RECEPTOR AGONISTS ELZEIN ELFATIH 2009-06-18 — — US disclosed
US-7514417-B2 A1 adenosine receptor agonists CV THERAPEUTICS, INC. (US) 2009-04-07 — — US disclosed
US-7381714-B2 A1 adenosine receptor agonists CV THERAPEUTICS, INC. (US) 2008-06-03 — — US disclosed
EP-1883646-A1 A1 ADENOSINE RECEPTOR AGONISTS CV THERAPEUTICS, INC. (US) 2008-02-06 — — EP disclosed
EP-1881991-A1 A1 ADENOSINE RECEPTOR AGONISTS CV THERAPEUTICS, INC. (US) 2008-01-30 — — EP disclosed
US-7238676-B2 Purine derivatives PFIZER INC. (US) 2007-07-03 — — US disclosed
US-20060281705-A1 A1 adenosine receptor agonists CV THERAPEUTICS, INC. 2006-12-14 — — US disclosed
US-6677316-B2 TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL SMITHKLINE BEECHAM CORPORATION 2004-01-13 — — US disclosed
US-6610665-B1 Treatment of inflammatory diseases, asthma or chronic obstructive pulmonary disease SMITHKLINE BEECHAM CORPORATION 2003-08-26 — — US disclosed
US-20030096788-A1 Adenosine derivatives GLAXO WELLCOME INC. 2003-05-22 — — US disclosed
US-6492348-B1 Adenosine derivatives SMITHKLINE BEECHAM CORPORATION 2002-12-10 — — US disclosed
EP-1056759-B1 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES GLAXO GROUP LTD (GB) 2002-09-04 — — EP disclosed
US-20020032168-A1 Purine derivatives PFIZER INC. 2002-03-14 — — US disclosed
EP-1090019-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-04-11 — — EP disclosed
EP-1056759-A1 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES GLAXO GROUP LIMITED (GB) 2000-12-06 — — EP disclosed
WO-1999067262-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-12-29 — — WO disclosed
WO-1999041267-A1 2-(PURIN-9-YL) -TETRAHYDROFURAN-3, 4-DIOL DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156544-A1 A1 ADENOSINE RECEPTOR AGONISTS ADORA1, ADORA2A, ADORA3 LMNA 1717/4885TP53 3996/4885ALDH1A1 77/4885
US-20030096788-A1 Adenosine derivatives ADORA3, ADORA2A, ADORA1 LMNA 1446/4885TP53 4867/4885ALDH1A1 239/4885
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 LMNA 2144/4885TP53 1422/4885ALDH1A1 425/4885
US-20220378816-A1 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGONISTIC ACTIVITY ADORA2A, ADORA1, ADORA3 LMNA 3058/4885TP53 3907/4885ALDH1A1 495/4885
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 LMNA 2144/4885TP53 1422/4885ALDH1A1 425/4885
US-20060281705-A1 A1 adenosine receptor agonists ADORA1, ADORA2A, ADORA3 LMNA 1717/4885TP53 3996/4885ALDH1A1 77/4885
US-20020032168-A1 Purine derivatives ADORA2A, ADORA1, ADORA3 LMNA 2278/4885TP53 3188/4885ALDH1A1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.